US20230095374A1 - Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder - Google Patents
Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder Download PDFInfo
- Publication number
- US20230095374A1 US20230095374A1 US17/971,033 US202217971033A US2023095374A1 US 20230095374 A1 US20230095374 A1 US 20230095374A1 US 202217971033 A US202217971033 A US 202217971033A US 2023095374 A1 US2023095374 A1 US 2023095374A1
- Authority
- US
- United States
- Prior art keywords
- compound
- cas
- carbon atoms
- hydrogen
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 145
- 238000011282 treatment Methods 0.000 title claims abstract description 46
- 230000002265 prevention Effects 0.000 title claims abstract description 36
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 35
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 70
- 230000028327 secretion Effects 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 46
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 45
- 229910052760 oxygen Inorganic materials 0.000 claims description 45
- 239000001301 oxygen Substances 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 44
- SETVRSKZJJWOPA-FLDGXQSCSA-N ascochlorin Chemical compound C[C@@H]1CCC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O SETVRSKZJJWOPA-FLDGXQSCSA-N 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 210000001130 astrocyte Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- IJEHYEVNWOYGMS-WGUBEYSISA-N 5-chloro-2,4-dihydroxy-6-methyl-3-[(e)-3-methyl-5-[(1s,2r,6r)-1,2,6-trimethyl-3-oxocyclohexyl]pent-2-enyl]benzaldehyde Chemical compound C[C@@H]1CCC(=O)[C@H](C)[C@@]1(C)CC\C(C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O IJEHYEVNWOYGMS-WGUBEYSISA-N 0.000 claims description 16
- SHZXWVNJUPKTJN-UHFFFAOYSA-N Ascochlorin Natural products CC1CCC(=O)C(C)C1C=CC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O SHZXWVNJUPKTJN-UHFFFAOYSA-N 0.000 claims description 16
- ACSLMZYXJATICN-IRMIYARYSA-N [(1s,2s,3s,4r)-3-[(1e,3e)-5-(3-chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-3-methylpenta-1,3-dienyl]-2,3,4-trimethyl-5-oxocyclohexyl] acetate Chemical compound C[C@@H]1[C@@H](OC(C)=O)CC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O ACSLMZYXJATICN-IRMIYARYSA-N 0.000 claims description 16
- 230000032050 esterification Effects 0.000 claims description 7
- 238000005886 esterification reaction Methods 0.000 claims description 7
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000002298 terpene group Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 abstract description 16
- 235000013305 food Nutrition 0.000 abstract description 13
- 150000003505 terpenes Chemical group 0.000 description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 210000002569 neuron Anatomy 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- JIHNIFVHUVCKQA-NTUHNPAUSA-N CC1CCC(=O)C(C)C1(C)CC(OC(C)=O)C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O Chemical compound CC1CCC(=O)C(C)C1(C)CC(OC(C)=O)C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O JIHNIFVHUVCKQA-NTUHNPAUSA-N 0.000 description 12
- JIHNIFVHUVCKQA-UHFFFAOYSA-N Chloronectrin Natural products CC1CCC(=O)C(C)C1(C)CC(OC(C)=O)C(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O JIHNIFVHUVCKQA-UHFFFAOYSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 210000004413 cardiac myocyte Anatomy 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 8
- 208000010877 cognitive disease Diseases 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 229930010828 amorfrutin Natural products 0.000 description 6
- CTNFTPUIYFUXBE-UHFFFAOYSA-N amorfrutin 1 Chemical compound OC1=C(CC=C(C)C)C(OC)=CC(CCC=2C=CC=CC=2)=C1C(O)=O CTNFTPUIYFUXBE-UHFFFAOYSA-N 0.000 description 6
- 150000008030 amorfrutins Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 239000000446 fuel Substances 0.000 description 6
- 239000002417 nutraceutical Substances 0.000 description 6
- 235000021436 nutraceutical agent Nutrition 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- AQCKKGIVKOHRLM-HBFAXEOFSA-N C[C@@H]1CCC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C=C(C)C(C=O)=C1O Chemical compound C[C@@H]1CCC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C=C(C)C(C=O)=C1O AQCKKGIVKOHRLM-HBFAXEOFSA-N 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000007824 enzymatic assay Methods 0.000 description 5
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003925 brain function Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000006999 cognitive decline Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- JSPPDMSCDGJJOM-YDMRWXCBSA-N 2,4-dihydroxy-6-methyl-3-[(e)-3-methyl-5-[(1s,2r,6r)-1,2,6-trimethyl-3-oxocyclohexyl]pent-2-enyl]benzaldehyde Chemical compound C[C@@H]1CCC(=O)[C@H](C)[C@@]1(C)CC\C(C)=C\CC1=C(O)C=C(C)C(C=O)=C1O JSPPDMSCDGJJOM-YDMRWXCBSA-N 0.000 description 3
- 206010003805 Autism Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 208000009132 Catalepsy Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 201000000251 Locked-in syndrome Diseases 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010028570 Myelopathy Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 208000000323 Tourette Syndrome Diseases 0.000 description 3
- 208000016620 Tourette disease Diseases 0.000 description 3
- 206010047853 Waxy flexibility Diseases 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 230000019439 energy homeostasis Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 208000027061 mild cognitive impairment Diseases 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- QPIZDZGIXDKCRC-JTCWOHKRSA-N 2,4-dihydroxy-6-methyl-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzoic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC1=C(O)C=C(C)C(C(O)=O)=C1O QPIZDZGIXDKCRC-JTCWOHKRSA-N 0.000 description 2
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 2
- SXOCWLUWTFGULD-MDWZMJQESA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-methylbenzaldehyde Chemical compound CC(C)=CCC\C(C)=C\CC1=C(O)C=C(C)C(C=O)=C1O SXOCWLUWTFGULD-MDWZMJQESA-N 0.000 description 2
- ZLAQYJKDQSZARB-FLDGXQSCSA-N 5-chloro-2,4-dihydroxy-6-methyl-3-[(2e,4e)-3-methyl-5-[(1s,2r,6r)-1,2,6-trimethyl-5-oxocyclohex-3-en-1-yl]penta-2,4-dienyl]benzaldehyde Chemical compound C[C@@H]1C=CC(=O)[C@H](C)[C@@]1(C)\C=C\C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O ZLAQYJKDQSZARB-FLDGXQSCSA-N 0.000 description 2
- UEUMAXMCCDEOIJ-XYOKQWHBSA-N 5-chloro-3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-methylbenzaldehyde Chemical compound CC(C)=CCC\C(C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O UEUMAXMCCDEOIJ-XYOKQWHBSA-N 0.000 description 2
- IJEHYEVNWOYGMS-UHFFFAOYSA-N Antibiotic LL-Z 1272delta Natural products CC1CCC(=O)C(C)C1(C)CCC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O IJEHYEVNWOYGMS-UHFFFAOYSA-N 0.000 description 2
- 208000022316 Arachnoid cyst Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021034 Hypometabolism Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 229930182504 Lasalocid Natural products 0.000 description 2
- 102000017298 Monocarboxylate transporters Human genes 0.000 description 2
- 108050005244 Monocarboxylate transporters Proteins 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229930010822 amorfrutin 4 Natural products 0.000 description 2
- UAMAHWUELDAAIA-LDADJPATSA-N amorfrutin 4 Chemical compound OC(=O)C1=C(O)C(C/C=C(C)/CCC=C(C)C)=C(O)C=C1CCC1=CC=CC=C1 UAMAHWUELDAAIA-LDADJPATSA-N 0.000 description 2
- BGYWMHFOMULQIA-UHFFFAOYSA-N amorfrutin B Natural products COc1cc(CCc2ccccc2)c(C(O)=O)c(O)c1CCC(C)CCC=C(C)C BGYWMHFOMULQIA-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- AQCKKGIVKOHRLM-UHFFFAOYSA-N dechloroilicicolin D Natural products CC1CCC(=O)C(C)C1(C)C=CC(C)=CCC1=C(O)C=C(C)C(C=O)=C1O AQCKKGIVKOHRLM-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- ACSLMZYXJATICN-UHFFFAOYSA-N ilicicolin F Natural products CC1C(OC(C)=O)CC(=O)C(C)C1(C)C=CC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O ACSLMZYXJATICN-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229960000320 lasalocid Drugs 0.000 description 2
- -1 linalyl Chemical group 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- GLOBOHBQKQLVIS-UHFFFAOYSA-N 2-(3-methylbut-2-enyl)phenol Chemical compound CC(C)=CCC1=CC=CC=C1O GLOBOHBQKQLVIS-UHFFFAOYSA-N 0.000 description 1
- XFTFIFNAWKMLKL-UHFFFAOYSA-N 4'-Hydroxy-5'-hydroascochlorin Natural products CC1CCC(=O)C(C)C1(C)CC(O)C(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O XFTFIFNAWKMLKL-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- DVURAWKKNXOYHO-LHDPSMIPSA-N 5-chloro-3-[(2E,6E,10S)-10,11-dihydroxy-3,7,11-trimethyldodeca-2,6-dienyl]-2,4-dihydroxy-6-methylbenzaldehyde Chemical compound CC(O)(C)[C@@H](O)CCC(/C)=C/CC\C(C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O DVURAWKKNXOYHO-LHDPSMIPSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 240000002066 Amorpha fruticosa Species 0.000 description 1
- 235000004047 Amorpha fruticosa Nutrition 0.000 description 1
- JSPPDMSCDGJJOM-UHFFFAOYSA-N Antibiotic LL-Z 1272epsilon Natural products CC1CCC(=O)C(C)C1(C)CCC(C)=CCC1=C(O)C=C(C)C(C=O)=C1O JSPPDMSCDGJJOM-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000222195 Ascochyta Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- XFTFIFNAWKMLKL-WUXMJOGZSA-N CC1CCC(=O)C(C)C1(C)CC(O)C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O Chemical compound CC1CCC(=O)C(C)C1(C)CC(O)C(\C)=C\CC1=C(O)C(Cl)=C(C)C(C=O)=C1O XFTFIFNAWKMLKL-WUXMJOGZSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000875119 Cylindrocarpon lucidum Species 0.000 description 1
- ZLAQYJKDQSZARB-UHFFFAOYSA-N Cylindrochlorin Natural products CC1C=CC(=O)C(C)C1(C)C=CC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O ZLAQYJKDQSZARB-UHFFFAOYSA-N 0.000 description 1
- 229930191136 Cylindrol Natural products 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241001149959 Fusarium sp. Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000674162 Glycyrrhiza foetida Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 241001435627 Nalanthamala diospyri Species 0.000 description 1
- 241000577892 Neonectria coccinea Species 0.000 description 1
- 241000556984 Neonectria galligena Species 0.000 description 1
- 241000369685 Nigrosabulum globosum Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 241000221841 Verticillium sp. (in: Hypocreales) Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229930010823 amorfrutin 1 Natural products 0.000 description 1
- 229930010820 amorfrutin C Natural products 0.000 description 1
- KTBAIBUBSGVINZ-UHFFFAOYSA-N amorfrutin C Chemical compound COC1=C(CC=C(C)C)C(O)=C(C(O)=O)C(CCC=2C=CC=CC=2)=C1CC=C(C)C KTBAIBUBSGVINZ-UHFFFAOYSA-N 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000036995 brain health Effects 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DVURAWKKNXOYHO-UHFFFAOYSA-N chlorocylindrocarpol Natural products CC(O)(C)C(O)CCC(C)=CCCC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O DVURAWKKNXOYHO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- UEUMAXMCCDEOIJ-UHFFFAOYSA-N colletochlorin B Natural products CC(C)=CCCC(C)=CCC1=C(O)C(Cl)=C(C)C(C=O)=C1O UEUMAXMCCDEOIJ-UHFFFAOYSA-N 0.000 description 1
- SXOCWLUWTFGULD-UHFFFAOYSA-N colletorin B Natural products CC(C)=CCCC(C)=CCC1=C(O)C=C(C)C(C=O)=C1O SXOCWLUWTFGULD-UHFFFAOYSA-N 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- QPIZDZGIXDKCRC-UHFFFAOYSA-N ilicicolinic acid B Natural products CC(C)=CCCC(C)=CCCC(C)=CCC1=C(O)C=C(C)C(C(O)=O)=C1O QPIZDZGIXDKCRC-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 235000020887 ketogenic diet Nutrition 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 239000002508 peroxisome proliferator activated receptor antagonist Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- the brain is a energy demanding organ as many processes linked to neurons and glial cells require a lot of energy in the form of ATP.
- electrical activity the restoration of ion gradients across the plasma membrane as well as synaptic transmission are examples of biological processes that require high levels of energy supply.
- the brain is therefore strongly dependent on the continuous provision of glucose as neurons do not store glycogen and are unable to oxidize fats as an alternative fuel source.
- Glucose metabolism is initiated in the glycolytic pathway that forms ATP, NADH and either of two end-products pyruvate or lactate.
- pyruvate oxidized in the mitochondrial matrix is required to initiate the synthesis of the large majority of ATP molecules to maintain neuronal energy homeostasis.
- the ability of cells of the central nervous system to generate sufficient amounts of energy is essential for brain function. In the aging brain, glucose metabolism is reduced, which may explain declining cognitive function as we get older.
- Glucose hypometabolism has also been observed in individuals at risk of developing Alzheimer's disease long before clinical symptoms are detected. Interventions improving brain energy metabolism may therefore be used to prevent cognitive decline during normal aging or neurological diseases.
- ketone bodies In addition to glucose, neurons are able to oxidize other fuels such as amino acids (mainly glutamate and glutamine), ketone bodies, lactate and pyruvate. During fasting for instance, ketone bodies serve as an important fuel source gradually replacing glucose during the transition from fasting to starvation. Lactate is a particularly important mitochondrial substrate. It is dehydrogenated to pyruvate, which can then be fully oxidized by mitochondria to form CO 2 . Oxidative metabolism of pyruvate is coupled to mitochondrial electron transport and respiration resulting in ATP synthesis. In the central nervous system, lactate also has a signaling function, stimulating for example hypoxia-induced factor 1 ⁇ and down-stream signaling causing transcriptional changes in brain cells.
- amino acids mainly glutamate and glutamine
- ketone bodies serve as an important fuel source gradually replacing glucose during the transition from fasting to starvation.
- Lactate is a particularly important mitochondrial substrate. It is dehydrogenated to pyruvate, which can
- lactate The source of lactate can be several fold. When neurons are electrically active, they accelerate their glycolytic pathway to the extent that mitochondria are no longer able to keep up with pyruvate oxidation. Instead, pyruvate is transiently converted to lactate in a process which has been termed aerobic glycolysis. In this situation, the accumulating lactate may exert its signaling role in neurons stabilizing for example hypoxia-induced factor 1 ⁇ or inducing the expression of brain-derived neurotrophic factor, which is important for neuronal survival and long-term memory.
- a second and even more important source of lactate are astrocytes. This cell type is metabolically closely linked both to neurons and cerebral blood vessel capillaries.
- astrocytes A main function of astrocytes is to sense synaptic activity and regulate the uptake as well as transfer of nutrients from the blood stream to neurons.
- Astrocytes are highly glycolytic. Their metabolism of glucose therefore mainly ends in the formation of lactate with only a fraction of pyruvate entering mitochondria for oxidation. Lactate synthesized by astrocytes is exported and taken up by neighboring neurons via monocarboxylate transporters. Here lactate serves as a fuel for neuronal mitochondria. This metabolic connection has been termed the astrocyte neuron lactate shuttle (ANLS).
- ANLS astrocyte neuron lactate shuttle
- a third source of lactate for the brain is the direct uptake from the periphery.
- lactate During exercise systemic blood concentrations of lactate increase and cross the blood brain barrier to be metabolized by neurons. In this way, peripherally generated lactate contributes to brain energy metabolism. Exercise has been shown to improve memory function. Lactate may be an important metabolite explaining this effect of exercise on learning.
- lactate The importance of lactate on learning has been convincingly demonstrated when studying the ANLS. Lowering the expression of specific monocarboxylate transporters impairs the transfer of lactate from astrocytes to neurons and thereby long-term memory formation.
- lactate either as a signaling molecule or as a fuel for mitochondria may influence neurological diseases where chronic or acute energy deficits need to be corrected.
- AD Alzheimer's disease
- Epilepsy is the fourth most common neurological disorder. Up to 30% of children with epilepsy continue to have seizures despite anticonvulsant treatment. Ketogenic diets successfully lower the frequency of seizures in children with intractable epilepsy. However, these diets are very high in fat and therefore highly unpalatable.
- Tissue plasminogen activator tPA
- ischemic stroke Stroke is the most common cause of handicap and the third most common cause of death in adults worldwide.
- Tissue plasminogen activator tPA
- the drawback of this treatment is that it can be effective only when administered during short time windows (within 3 hours) after ischemia.
- Endovascular procedure can be used to remove the clot blocking the artery but only after tPA treatment and within 6 hours of the ischemia. Strict criteria determine the eligibility of a patient for this procedure. Considering that only very limited treatment options exist, there is a need for new stroke treatments.
- Targeting brain metabolism may prove useful in stroke to rapidly restore energy supply as neurons are transiently deprived of oxygen and nutrients.
- stroke transient middle cerebral artery occlusion
- lactate has been successfully tested for its ability to prevent neuronal loss.
- modulating metabolism to enhance the availability of lactate for neurons may have beneficial effects in mild cognitive impairment during aging or neurological diseases with suspected energy deficits in neurons.
- meroterpenoids particularly ascochlorin and related compounds
- these active compounds affect the astrocyte neuron lactate shuttle or stimulate lactate release from other tissues and may thereby be beneficial for brain energy homeostasis and neuronal health by counteracting the negative effects of impaired metabolism.
- analogue as used herein is understood to refer to a compound having a structure similar to that of another one, but differing from it in respect of a certain component.
- a “derivative” is a compound that can be imagined to arise or actually be synthesized from a parent compound by replacement of one atom with another atom or group of atoms.
- Halogen can be a fluorine, chlorine, a bromine or an iodine atom.
- Isoprenoid chain the building blocks of which are five carbon branched-chain unsaturated hydrocarbons biosynthetically derived from dimethylallyl pyrophosphate and its isomer isopentenyl pyrophosphate. Unsaturated means it contains at least one double bond between carbon atoms. Isoprenoid chains may contain one or more of these unsaturated five carbon units.
- Isoprenoid chains may for example but not exclusively comprise 3,3-dimethyllalyl, 1,1-dimethylallyl, geranyl, linalyl, farnesyl, nerolidyl, and geranylgeranyl chains.
- “Modified isoprenoid” chain means that the original isoprenoid backbone has been further modified, biosynthetically and/or chemically. Such modifications may for example but not exclusively include reduction of double bonds, stepwise carbon oxidation to hydroxyl, aldehyde, and carboxylic acid groups, carbon loss, rearrangement of carbon atoms, rearrangement of double bonds, esterification of hydroxyls, amidation of carboxyls, cyclization.
- “Cyclized chain” is related to a chain having atoms arranged in a ring or closed-chain structure.
- “Hydroxylated” means a structure modified by hydroxylation, i.e. the introduction of a hydroxyl group.
- “Open chain” is a chain with a linear structure, i.e. having no ring in its structure.
- a “modified phenethyl chain” means that the original phenethyl backbone has been further modified, biosynthetically and/or chemically. Such modifications may for example but not exclusively include reduction of the double bond.
- compositions disclosed herein may lack any element that is not specifically disclosed herein.
- a disclosure of an embodiment using the term “comprising” includes a disclosure of embodiments “consisting essentially of” and “consisting of” the components identified.
- a composition “consisting essentially of” contains at least 50 wt. % of the referenced components, preferably at least 75 wt. % of the referenced components, more preferably at least 85 wt. % of the referenced components, most preferably at least 95 wt. % of the referenced components.
- compositions mean a product or composition that is intended for ingestion by an individual such as a human and provides at least one nutrient to the individual.
- compositions of the present disclosure can comprise, consist of, or consist essentially of the elements disclosed herein, as well as any additional or optional ingredients, components, or elements described herein or otherwise useful in a diet.
- Cognitive function is responsible for brain functions including the processing of information, memory capacities, situation dependent judgment, learning ability and memory.
- cognitive impairment during aging means a reduction of cognitive function or impairment of any subcategory linked to brain function compared to the control healthy individual when using cognitive testing.
- Such cognitive testing usually includes measures of memory, language, ability to orient and attention span.
- meroterpenoid refers to a class of natural products of mixed biosynthetic origin which are partially derived from terpenoids.
- neurological disorder means any disorder of the nervous system. Such disorders can be the result of disease and accelerated loss of brain function during aging but could also be due to genetic variations or caused by malnutrition.
- prevention includes reduction of risk and/or severity of a condition or disorder.
- treatment includes both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder, and include treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition. The term does not necessarily imply that an individual is treated until total recovery.
- treatment also refers to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition.
- treatment also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure.
- treatment also intended to include the dietary management of a disease or condition or the dietary management for prophylaxis or prevention a disease or condition.
- a treatment can be patient- or doctor-related.
- the term “individual” means any animal, including humans, that could suffer from a neurological disorder and thus benefit from one or more of the methods disclosed herein.
- the individual is a human or an avian, bovine, canine, equine, feline, hicrine, lupine, murine, ovine or porcine animal.
- a “companion animal” is any domesticated animal, and includes, without limitation, cats, dogs, rabbits, guinea pigs, ferrets, hamsters, mice, gerbils, horses, cows, goats, sheep, donkeys, pigs, and the like.
- the individual is a human or a companion animal such as a dog or cat.
- the compound of the invention can be used for the prevention or treatment of disorders relating to brain health, particularly neurological disorders.
- a human individual who is elderly may benefit.
- An individual is considered as “elderly” if it has surpassed the first half of its average expected lifespan in its country of origin, preferably, if it has surpassed the first two thirds of the average expected lifespan in its country of origin, more preferably if it has surpassed the first three quarters of the average expected lifespan in its country of origin, most preferred if it has surpassed the first four fifths of the average expected lifespan in its country of origin.
- a human individual who is an infant under 5 years of age may also benefit.
- an “effective amount” is an amount that prevents a deficiency, treats a disease or medical condition in an individual or, more generally, reduces symptoms, manages progression of the diseases or provides a nutritional, physiological, or medical benefit to the individual.
- the relative terms “improved,” “increased,” “enhanced” and the like refer to the effects of the composition disclosed herein relative to a composition lacking one or more ingredients and/or having a different amount of one or more ingredients, but otherwise identical.
- the present invention relates to a compound of structural formula (la)
- R1 H or a halogen
- R2 an isoprenoid chain or a modified isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH.
- R1 H or a halogen
- R2 an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH.
- R1 H or a halogen
- R2 an isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH.
- R1 H or a halogen
- R2 an isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH.
- R1 a halogen
- R2 an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH.
- R1 a halogen
- R2 an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen
- R3 H or OH
- R1 halogen
- R2 an isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen
- R3 H or OH.
- R1 halogen
- R2 an isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen
- R3 H or OH.
- R1 Cl
- R2 an isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen
- R3 H.
- compounds of structural formula (Ia) can be represented as follows:
- the compound is for use in the prevention and/or treatment of a neurological disorder in an individual wherein lactate secretion is promoted.
- the compound is for use in the prevention and/or treatment of a neurological disorder in an individual wherein lactate secretion from astrocytes is promoted.
- the compound is for use in the prevention and/or treatment of a neurological disorder in an individual wherein lactate secretion is promoted from peripheral tissues.
- the compound is for use in the prevention of cognitive decline in an individual wherein lactate secretion is promoted.
- the individual is a human, in particular an elderly human individual or an infant human individual. In one embodiment, the individual is a companion animal.
- the compound is a meroterpenoid. In one embodiment, the compound can be found in nature.
- the compound is an isoprenoid phenol. In one embodiment, the compound is a prenyl phenol. In one embodiment, the compound is a terpenoid derivative.
- the compound has structural formula (Ib).
- R1 H or a halogen
- R2 a cyclized isoprenoid chain or a modified cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH.
- R1 H or a halogen
- R2 a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH
- R1 H or a halogen
- R2 a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH
- R1 H or a halogen
- R2 a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH
- R1 a halogen
- R2 a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen
- R3 H or OH
- R1 a halogen
- R2 a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen
- R3 H or OH
- R1 a halogen
- R2 a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen
- R3 H or OH
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen
- R3 H.
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen
- R3 H.
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen
- R3 H.
- compounds of structural formula (Ib) can be represented as follows:
- R1 Cl
- R3 H.
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H.
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and optionally oxygen
- R3 H.
- R1 H or a halogen
- R2 a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen
- R3 H.
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen
- R3 H.
- R1 Cl
- R2 a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen
- R3 H.
- the compound may be selected from the list comprising CAS 26166-39-2 (Ascochlorin or Ilicicolin D); CAS 22562-68-1 (Antibiotic LL-Z 1272 ⁇ ); CAS 165187-16-6 (Cylindrol B); CAS 22562-67-0 (Ilicicolin C); CAS 23887-67-4 (Ilicicolin E); CAS 22738-98-3 (Ilicicolin F); CAS 80557-12-6 (Grifolic acid); and CAS 22851-11-9.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D), or an analogue or derivative thereof.
- the compound is CAS 22562-67-0 (Illicicolin C), or an analogue or derivative thereof.
- the compound is CAS 22738-98-3 (Illicicolin F), or an analogue or derivative thereof.
- Ascochlorin and derivatives thereof can be found in or produced by fungal species, for example Acremonium sp., Acremoninum luculae, Ascochyta oiciae, Asochyta viciae, Cephalosporium diospyri, Cylindrocarpon lucidum, Fusarium sp., Nectria galligena, Nectria coccinea, Nigrosabulum globosum, Verticillium sp.
- fungal species for example Acremonium sp., Acremoninum luculae, Ascochyta oiciae, Asochyta viciae, Cephalosporium diospyri, Cylindrocarpon lucidum, Fusarium sp., Nectria galligena, Nectria coccinea, Nigrosabulum globosum, Verticillium sp.
- said compound has structural formula (Ic).
- R1 H or a halogen
- R2 a cyclized isoprenoid chain with further hydroxylated side chain structure or a modified cyclized isoprenoid chain structure with further hydroxylated side chain structure and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optimally oxygen
- R1 H or a halogen
- R2 a cyclized isoprenoid chain with further hydroxylated side chain structure or a modified cyclized isoprenoid chain structure with further hydroxylated side chain structure and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optimally oxygen
- R3 H or OH.
- compounds of structural formula (Ic) can be represented as follows:
- R1 Cl
- R3 H.
- R2 a cyclized isoprenoid chain with further hydroxylated side chain structure and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optimally oxygen.
- R1 Cl
- R3 H
- R2 a cyclized isoprenoid chain with further hydroxylated side chain structure and further esterification comprising 1 to 19 carbon atoms, hydrogen, and oxygen.
- R1 Cl
- R3 H
- R2 a cyclized isoprenoid chain with further hydroxylated side chain structure and further esterification comprising 1 to 10 carbon atoms, hydrogen, and oxygen.
- R1 Cl
- R3 H
- R2 a cyclized isoprenoid chain with further hydroxylated side chain structure and further esterification comprising 1 to 5 carbon atoms, hydrogen, and oxygen.
- said compound may be selected from the list comprising CAS 38561-36-3 (Deacetylchloronectrin); CAS 53730-27-1 (Hydroxyhydroascochlorin); CAS 38965-84-3 (Chloronectrin); CAS 1654004-69-9 (Nectchlorin A); CAS 165187-17-7 (Cylindrol A4); and CAS 1651819-33-8.
- the compound is CAS 38965-84-3 (Chloronectrin) or an analogue or derivative thereof.
- said compound has structural formula (Id).
- R1 H or a halogen
- R2 an open isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H or OH.
- compounds of structural formula (Id) can be represented as follows:
- said compound may be selected from the list comprising CAS 83324-56-5 (Colletorin B); CAS 83324-48-5 (Colletochlorin B); CAS 22581-07-3 (Illicicolin B), CAS 22581-06-2 (Illicicolin A), CAS 1114927-87-5 (Chlorocylindrocarpol), and CAS1654004-70-2 (Nectchlorin B).
- the present invention also relates to a compound having a structural formula (II).
- R1 phenethyl or a modified phenethyl side chain, and/or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R2 H or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- R3 H or methyl
- R4 an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen. or a salt thereof for use in the prevention and/or treatment of a neurological disorder in an individual.
- compounds of structural formula (II) can be represented as follows:
- the compound of structural formula (II) is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted.
- the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion from astrocytes is promoted.
- the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted in peripheral locations.
- the compound is for use in the prevention of cognitive decline in an individual wherein lactate secretion is promoted.
- Amorfrutins may be obtained, for example, from the fruits of Amorpha fruticosa or the roots of Glycyrrhiza foetida.
- the present invention also relates to a compound having a structural formula (III).
- R1 an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- compounds of structural formula (III) can be represented as follows:
- the compound of structural formula (III) is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted.
- the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion from astrocytes is promoted.
- the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted in peripheral locations.
- the compound is for use in the prevention of cognitive decline in an individual wherein lactate secretion is promoted.
- said compound may be CAS 25999-31-9 (Lasalocid)
- composition comprising an effective amount of the compound of the invention, for use in the prevention or treatment of a neurological disorder in an individual.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- said composition is a pharmaceutical or nutraceutical composition.
- nutraceutical combines the words “nutrition” and “pharmaceutical”. It is a food or food product that provides health and medical benefits, including the prevention and treatment of disease.
- a nutraceutical is a product isolated or purified from foods that is generally sold in medicinal forms not usually associated with food. A nutraceutical is demonstrated to have a physiological benefit or provide protection against chronic disease. Such products may range from isolated nutrients, dietary supplements and specific diets to genetically engineered foods, herbal products, and processed foods such as cereals, soups, and beverages.
- nutraceutical as used herein denotes usefulness in both nutritional and pharmaceutical fields of application.
- novel nutraceutical compositions can be used as supplements to food and beverages and as pharmaceutical formulations for enteral or parenteral application which may be solid formulations, such as capsules or tablets, or liquid formulations, such as solutions or suspensions.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- the compound of the invention can be used for the promotion of lactate secretion in an individual.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- the compound of the invention can be used for the prevention or treatment of a neurological disorder, for memory dysfunction or for mild cognitive impairment in an individual.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- the compound of the invention is used for the prevention or treatment of a neurological disorder.
- a neurological disorder include disorders of the central nervous system such as addiction; arachnoid cysts; attention deficit/hyperactivity disorder (ADHD); Autism; Bipolar disorder; Catalepsy; Depression; Encephalitis; Epilepsy/Seizures; Infection; Locked-in syndrome; Meningitis; Migraine; Multiple sclerosis; Myelopathy.
- Neurological disorders may also include neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and Tourette's syndrome.
- the neurological disorder may be selected from addiction; arachnoid cysts; attention deficit/hyperactivity disorder (ADHD); Autism; Bipolar disorder; Catalepsy; Depression; Encephalitis; Epilepsy/Seizures; Infection; Locked-in syndrome; Meningitis; Migraine; Myelopathy.
- Neurological disorders may also include neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and Tourette's syndrome.
- the neurological disorder may be selected from attention deficit/hyperactivity disorder (ADHD); Autism; Bipolar disorder; Catalepsy; Infection; Locked-in syndrome; Meningitis; Migraine; Myelopathy.
- ADHD attention deficit/hyperactivity disorder
- Autism Autism
- Bipolar disorder Catalepsy
- Infection Locked-in syndrome
- Meningitis Meningitis
- Migraine Myelopathy.
- the neurological disorder may be selected from Alzheimer's disease, Huntington's disease, Parkinson's disease, and Tourette's syndrome.
- the compound of the invention can also be used for the prevention or treatment of diabetes and/or diabetes-related disorders, particularly Type II diabetes, counteracting of insulin resistance, complications of diabetes, protection of pancreatic Langerhans islet beta-cells, antidiabetic therapies, therapy of syndrome X, diabetic neurosis, diabetic nephropathy, diabetic retinopathy, and for lifestyle-related diseases in an individual.
- diabetes and/or diabetes-related disorders particularly Type II diabetes, counteracting of insulin resistance, complications of diabetes, protection of pancreatic Langerhans islet beta-cells, antidiabetic therapies, therapy of syndrome X, diabetic neurosis, diabetic nephropathy, diabetic retinopathy, and for lifestyle-related diseases in an individual.
- the compound of the invention is used for the protection of pancreatic Langerhans islet beta-cells, therapy of syndrome X, or diabetic neurosis.
- the compound of the invention is used for the protection of pancreatic Langerhans islet beta-cells.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- the compound of the invention can also be used for the prevention or treatment of disorders relating to lipid metabolism, particularly to those of the ligand of retinoid X receptor, ligand of nuclear receptor, PPAR-Agonist, PPAR-Antagonist, ligands activating nuclear receptor super family, and to the improvement of lipid metabolism, and antilipemic disease in an individual.
- the compound of the invention can also be used for the prevention or treatment of disorders related to vascular complications, particularly arteriosclerosis, hypertension, cerebrovascular diseases, hypotensive, hypertension, traumatic brain injury and cerebrovascular disorders in an individual.
- disorders related to vascular complications particularly arteriosclerosis, hypertension, cerebrovascular diseases, hypotensive, hypertension, traumatic brain injury and cerebrovascular disorders in an individual.
- the compound of the invention can also be used for the prevention or treatment of cancer, particularly to control tumors, and digestive cancers in an individual.
- the compound of the invention can also be used for the prevention or treatment of inflammatory diseases, particularly rheumatoid arthritis, chronic inflammation, vascular chronic inflammation and the like in an individual.
- the compound of the invention can also be used as a stimulator of AMPK activity in an individual.
- the compound of the invention can also be used for the prevention or treatment of a series of other disorders, autoimmune diseases, anorectic, restenosis, myxedema, and cachexia in an individual.
- the present invention also relates to the use of a compound of structural formula (Ia), (Ib), (Ic), I(d), (II), or (III) in the preparation of a product for the promotion of lactate secretion in an individual.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- the present invention also relates to the use of a compound of structural formula (Ia), (Ib), (Ic), I(d), (II), or (III) in the preparation of a product for the prevention or treatment of a neurological disorder in an individual.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- the present invention also relates to the use of a compound of formula (Ia), (Ib), (Ic), I(d), (II), or (III) in the preparation of a diet product.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- the present invention also relates to a method for the prevention or treatment of a neurological disorder comprising administering a compound of formula (Ia), (Ib), (Ic), I(d), (II), or (III) to an individual.
- the compound is selected from Table 2.
- the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D).
- the compound is CAS 22562-67-0 (Illicicolin C).
- the compound is CAS 22738-98-3 (Illicicolin F),
- the compound is CAS 38965-84-3 (Chloronectrin).
- FIG. 1 shows the lactate screening strategy and the general workflow of the lactate release from the astrocytes drug discovery screen.
- Human astrocytoma cell line CCF-STTG1 was cultured at 37° C. in a humidified atmosphere (5% CO 2 ) in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 50 ⁇ g/ml penicillin and 100 ⁇ g/ml streptomycin.
- CCF-STTG1 were seeded in 384-well plates. Two days later, the cells were washed 3 times and incubated 30 min in Krebs-Ringer bicarbonate HEPES (KRBH) buffer containing (in mM): 140 NaCl, 3.6 KCl, 0.5 NaH2PO4, 0.5 MgSO4, 1.5 CaCl2, 10 HEPES, 5 NaHCO 3 (pH7.4) supplemented with 2.5 mM glucose. Then, the cells were maintained in the buffer in the presence of tested compounds. Supernatants were collected after 2 hours and were assessed for lactate concentration. Lactate concentration in the supernatants were determined by fluorescent enzymatic assay.
- KRBH Krebs-Ringer bicarbonate HEPES
- Samples were diluted in assay reagent containing (in mM or U/ml)): 100 sodium phosphate (pH7.5), 0.1 EDTA, 0.05 Amplex UltraRed, 0.1 Lactate oxidase, 1.5 Horseradish Peroxidase.
- Fluorescence emission was measured at 600 nm after an excitation at 500 nm using Bioteck Synergie Neo multimode reader after 30 min at room temperature protected from direct light.
- the compounds were also tested in absence of cells using the same fluorescent enzymatic assay described previously to assess their auto fluorescence or their interaction with the enzymatic assay. Fluorescence emission was measured at 600 nm after an excitation at 500 nm using Bioteck Synergie Neo multimode reader after 30 min at room temperature and protected from direct light. Fluorescence was then compared to control fluorescence obtained in basal and stimulated cells.
- KRBH Krebs-Ringer bi
- lactate secretion after treatment with meroterpenoid compounds was confirmed in an orthogonal assay based on another enzyme to measure lactate.
- the results of the lactate release measurement during the drug discovery screen for each compound and the results of lactate release measure with the orthogonal assay were correlated.
- Dose response curves were established for compounds identified in the screen to stimulate lactate secretion.
- the EC50 values for the stimulation of lactate secretion were determined using primary human IPS cell derived astrocytes.
- iPSCs Differentiated human iPSCs (iCell astrocytes, and iCell cardiomyocytes) were obtained from Cellular Dynamics International (CDI, Madison, Wis., USA). iCell astrocytes were cultured in DMEM supplemented with 10% fetal calf serum and N2 complement. iCell cardiomyocytes were maintained in a medium supplied by CDI. Cell cultures were kept in a humidified atmosphere (5% CO 2 ) at 37° C.
- FIGS. 2 A- 2 J shows lactate release. Dose response of compounds on lactate release from human iPSc derived into astrocyte fitted with a log (agonist) vs. response variable slope to extract efficacy (EC50). Mean ⁇ SEM in duplicate.
- iCell Cardiomyocytes were seeded in 384-well plates. Eight days later cells were treated for 24 hours with compounds. Cell viability was determined by the quantification of intracellular ATP after cell lysis. ATP was used as an indicator of metabolically active cells. ATP was measured using a luminescent cell viability assay (CellTiter-Glo®; BioRad, Hercules, Calif., USA). Luminescence was measured after 20 min in a Bioteck Synergie Neo multimode reader.
- Toxicity of the meroterpenoid compounds were evaluated in human IPS cell derived cardiomyocytes by measuring total ATP in cell lysates. Dose response experiments revealed that meroterpenoid compounds stimulated lactate secretion from astrocytes at concentrations several orders of magnitude below the concentration where they caused toxicity in cardiomyocytes.
- FIGS. 3 A- 3 I shows toxicity. Dose response of compounds on human iPSc derived into cardiomyocyte with evaluation of the ATP level using cell titer glow. Results were normalized between untreated cells (100%) and positive control (0%).
- Table 1 and Table 2 show a list of compounds of interest
- the toxicity expressed in log IC50 (ATP content after 24 hours compound treatment on human iPSc derived into cardiomyocyte) was compared against the lactate release in log EC50 (lactate secretion after 2 hours compound treatment in human iPSc derived into astrocytes).
- Meroterpenoid tested compounds showed a range of concentration where they are active on lactate secretion by astrocytes and not toxic on cardiomyocytes.
- FIG. 1 shows the lactate screening strategy
- FIGS. 2 A- 2 J show lactate release.
- Y-axis relative fluorescence unit
- X-axis logarithm concentration of the compound in molar.
- the structures of the compounds corresponding to graphs A-J are shown below.
- FIGS. 3 A- 3 I show toxicity.
- Y-axis relative fluorescence unit in percentage
- X-axis logarithm concentration of the compound in Molar.
- the structures of the compounds corresponding to graphs A-I are shown below.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a compound, in particular a meroterpenoid compound, or salt thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition is also provided.
Description
- The present application is a continuation of U.S. patent application Ser. No. 16/647,229 filed on Mar. 13, 2020, which is a National Stage of International Application No. PCT/EP2018/074805 filed on Sep. 13, 2018, which claims priority to European Patent Application No. 17191464.1 filed on Sep. 15, 2017, the entire contents of which are incorporated herein by reference.
- The brain is a energy demanding organ as many processes linked to neurons and glial cells require a lot of energy in the form of ATP. In neurons, electrical activity, the restoration of ion gradients across the plasma membrane as well as synaptic transmission are examples of biological processes that require high levels of energy supply. The brain is therefore strongly dependent on the continuous provision of glucose as neurons do not store glycogen and are unable to oxidize fats as an alternative fuel source.
- Glucose metabolism is initiated in the glycolytic pathway that forms ATP, NADH and either of two end-products pyruvate or lactate. In a second step, pyruvate oxidized in the mitochondrial matrix is required to initiate the synthesis of the large majority of ATP molecules to maintain neuronal energy homeostasis. The ability of cells of the central nervous system to generate sufficient amounts of energy is essential for brain function. In the aging brain, glucose metabolism is reduced, which may explain declining cognitive function as we get older. Glucose hypometabolism has also been observed in individuals at risk of developing Alzheimer's disease long before clinical symptoms are detected. Interventions improving brain energy metabolism may therefore be used to prevent cognitive decline during normal aging or neurological diseases.
- In addition to glucose, neurons are able to oxidize other fuels such as amino acids (mainly glutamate and glutamine), ketone bodies, lactate and pyruvate. During fasting for instance, ketone bodies serve as an important fuel source gradually replacing glucose during the transition from fasting to starvation. Lactate is a particularly important mitochondrial substrate. It is dehydrogenated to pyruvate, which can then be fully oxidized by mitochondria to form CO2. Oxidative metabolism of pyruvate is coupled to mitochondrial electron transport and respiration resulting in ATP synthesis. In the central nervous system, lactate also has a signaling function, stimulating for example hypoxia-induced factor 1α and down-stream signaling causing transcriptional changes in brain cells.
- The source of lactate can be several fold. When neurons are electrically active, they accelerate their glycolytic pathway to the extent that mitochondria are no longer able to keep up with pyruvate oxidation. Instead, pyruvate is transiently converted to lactate in a process which has been termed aerobic glycolysis. In this situation, the accumulating lactate may exert its signaling role in neurons stabilizing for example hypoxia-induced factor 1α or inducing the expression of brain-derived neurotrophic factor, which is important for neuronal survival and long-term memory. A second and even more important source of lactate are astrocytes. This cell type is metabolically closely linked both to neurons and cerebral blood vessel capillaries. A main function of astrocytes is to sense synaptic activity and regulate the uptake as well as transfer of nutrients from the blood stream to neurons. Astrocytes are highly glycolytic. Their metabolism of glucose therefore mainly ends in the formation of lactate with only a fraction of pyruvate entering mitochondria for oxidation. Lactate synthesized by astrocytes is exported and taken up by neighboring neurons via monocarboxylate transporters. Here lactate serves as a fuel for neuronal mitochondria. This metabolic connection has been termed the astrocyte neuron lactate shuttle (ANLS).
- A third source of lactate for the brain is the direct uptake from the periphery. During exercise systemic blood concentrations of lactate increase and cross the blood brain barrier to be metabolized by neurons. In this way, peripherally generated lactate contributes to brain energy metabolism. Exercise has been shown to improve memory function. Lactate may be an important metabolite explaining this effect of exercise on learning.
- The importance of lactate on learning has been convincingly demonstrated when studying the ANLS. Lowering the expression of specific monocarboxylate transporters impairs the transfer of lactate from astrocytes to neurons and thereby long-term memory formation.
- Modulation of lactate levels in the brain therefore has the potential to improve cognitive function. At the same time lactate either as a signaling molecule or as a fuel for mitochondria may influence neurological diseases where chronic or acute energy deficits need to be corrected.
- Alzheimer's disease (AD) is the most common cause of dementia. Currently, there is no cure for AD. Only symptomatic treatments exist, and these exert their beneficial effects mainly by restoring lowered neurotransmitter levels. Hypometabolism of glucose is a metabolic alteration likely occurring early during AD progression. Correction of brain metabolism is a promising approach to delay disease progression. Restoration of brain energy homeostasis has also been tested to restore mild cognitive impairment in the elderly.
- Epilepsy is the fourth most common neurological disorder. Up to 30% of children with epilepsy continue to have seizures despite anticonvulsant treatment. Ketogenic diets successfully lower the frequency of seizures in children with intractable epilepsy. However, these diets are very high in fat and therefore highly unpalatable.
- In epilepsy, local excessive electrical activity may result in the inability of neurons to cope with their energy load and the rapid provision of mitochondrial fuel may be beneficial. Transient formation of peripheral lactate or enhanced provision through the ANLS could be protective for neurons during recovery from a seizure.
- Stroke is the most common cause of handicap and the third most common cause of death in adults worldwide. Tissue plasminogen activator (tPA) is the only Federal Drug Administration-approved treatment for ischemic stroke. The drawback of this treatment is that it can be effective only when administered during short time windows (within 3 hours) after ischemia.
- Endovascular procedure can be used to remove the clot blocking the artery but only after tPA treatment and within 6 hours of the ischemia. Strict criteria determine the eligibility of a patient for this procedure. Considering that only very limited treatment options exist, there is a need for new stroke treatments.
- Targeting brain metabolism may prove useful in stroke to rapidly restore energy supply as neurons are transiently deprived of oxygen and nutrients. In a preclinical model of stroke (transient middle cerebral artery occlusion), lactate has been successfully tested for its ability to prevent neuronal loss.
- Taken together, modulating metabolism to enhance the availability of lactate for neurons may have beneficial effects in mild cognitive impairment during aging or neurological diseases with suspected energy deficits in neurons.
- The inventors of the present application have identified meroterpenoids (particularly ascochlorin and related compounds) as bioactives that promote lactate secretion from astrocytes. These active compounds affect the astrocyte neuron lactate shuttle or stimulate lactate release from other tissues and may thereby be beneficial for brain energy homeostasis and neuronal health by counteracting the negative effects of impaired metabolism.
- As used in this disclosure and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a component” or “the component” includes two or more components.
- The term “analogue” as used herein is understood to refer to a compound having a structure similar to that of another one, but differing from it in respect of a certain component. A “derivative” is a compound that can be imagined to arise or actually be synthesized from a parent compound by replacement of one atom with another atom or group of atoms.
- All percentages expressed herein are by weight of the total weight of the composition unless expressed otherwise. As used herein, “about,” “approximately” and “substantially” are understood to refer to numbers in a range of numerals, for example the range of −10% to +10% of the referenced number, preferably −5% to +5% of the referenced number, more preferably −1% to +1% of the referenced number, most preferably −0.1% to +0.1% of the referenced number. All numerical ranges herein should be understood to include all integers, whole or fractions, within the range. Moreover, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 1 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
- The components of the chemical structures described herein can be defined as follows: as used herein, the term “Halogen” can be a fluorine, chlorine, a bromine or an iodine atom. As used herein “Isoprenoid chain”, the building blocks of which are five carbon branched-chain unsaturated hydrocarbons biosynthetically derived from dimethylallyl pyrophosphate and its isomer isopentenyl pyrophosphate. Unsaturated means it contains at least one double bond between carbon atoms. Isoprenoid chains may contain one or more of these unsaturated five carbon units. Isoprenoid chains may for example but not exclusively comprise 3,3-dimethyllalyl, 1,1-dimethylallyl, geranyl, linalyl, farnesyl, nerolidyl, and geranylgeranyl chains. “Modified isoprenoid” chain means that the original isoprenoid backbone has been further modified, biosynthetically and/or chemically. Such modifications may for example but not exclusively include reduction of double bonds, stepwise carbon oxidation to hydroxyl, aldehyde, and carboxylic acid groups, carbon loss, rearrangement of carbon atoms, rearrangement of double bonds, esterification of hydroxyls, amidation of carboxyls, cyclization. “Cyclized chain” is related to a chain having atoms arranged in a ring or closed-chain structure. “Hydroxylated” means a structure modified by hydroxylation, i.e. the introduction of a hydroxyl group. “Open chain” is a chain with a linear structure, i.e. having no ring in its structure. A “modified phenethyl chain” means that the original phenethyl backbone has been further modified, biosynthetically and/or chemically. Such modifications may for example but not exclusively include reduction of the double bond.
- The words “comprise,” “comprises” and “comprising” are to be interpreted inclusively rather than exclusively. Likewise, the terms “include,” “including” and “or” should all be construed to be inclusive, unless such a construction is clearly prohibited from the context. Nevertheless, the compositions disclosed herein may lack any element that is not specifically disclosed herein. Thus, a disclosure of an embodiment using the term “comprising” includes a disclosure of embodiments “consisting essentially of” and “consisting of” the components identified. A composition “consisting essentially of” contains at least 50 wt. % of the referenced components, preferably at least 75 wt. % of the referenced components, more preferably at least 85 wt. % of the referenced components, most preferably at least 95 wt. % of the referenced components.
- The term “and/or” used in the context of “X and/or Y” should be interpreted as “X,” or “Y,” or “X and Y.” Where used herein, the terms “example” and “such as,” particularly when followed by a listing of terms, are merely exemplary and illustrative and should not be deemed to be exclusive or comprehensive.
- The terms “food,” “food product” and “food composition” mean a product or composition that is intended for ingestion by an individual such as a human and provides at least one nutrient to the individual. The compositions of the present disclosure, including the many embodiments described herein, can comprise, consist of, or consist essentially of the elements disclosed herein, as well as any additional or optional ingredients, components, or elements described herein or otherwise useful in a diet.
- Cognitive function is responsible for brain functions including the processing of information, memory capacities, situation dependent judgment, learning ability and memory.
- The terms “impaired memory function during aging” and “cognitive impairment during aging” as used herein means a reduction of cognitive function or impairment of any subcategory linked to brain function compared to the control healthy individual when using cognitive testing. Such cognitive testing usually includes measures of memory, language, ability to orient and attention span.
- The term “meroterpenoid” refers to a class of natural products of mixed biosynthetic origin which are partially derived from terpenoids.
- The term “neurological disorder” as used herein means any disorder of the nervous system. Such disorders can be the result of disease and accelerated loss of brain function during aging but could also be due to genetic variations or caused by malnutrition.
- “Prevention” includes reduction of risk and/or severity of a condition or disorder. The terms “treatment,” “treat,” “attenuate” and “alleviate” include both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder, and include treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition. The term does not necessarily imply that an individual is treated until total recovery. These terms also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition. These terms are also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure. The terms “treatment,” “treat,” “attenuate” and “alleviate” are further intended to include the dietary management of a disease or condition or the dietary management for prophylaxis or prevention a disease or condition. A treatment can be patient- or doctor-related.
- The term “individual” means any animal, including humans, that could suffer from a neurological disorder and thus benefit from one or more of the methods disclosed herein. Generally, the individual is a human or an avian, bovine, canine, equine, feline, hicrine, lupine, murine, ovine or porcine animal. A “companion animal” is any domesticated animal, and includes, without limitation, cats, dogs, rabbits, guinea pigs, ferrets, hamsters, mice, gerbils, horses, cows, goats, sheep, donkeys, pigs, and the like. Preferably, the individual is a human or a companion animal such as a dog or cat. The compound of the invention can be used for the prevention or treatment of disorders relating to brain health, particularly neurological disorders.
- A human individual who is elderly may benefit. An individual is considered as “elderly” if it has surpassed the first half of its average expected lifespan in its country of origin, preferably, if it has surpassed the first two thirds of the average expected lifespan in its country of origin, more preferably if it has surpassed the first three quarters of the average expected lifespan in its country of origin, most preferred if it has surpassed the first four fifths of the average expected lifespan in its country of origin. A human individual who is an infant under 5 years of age, may also benefit.
- As used herein, an “effective amount” is an amount that prevents a deficiency, treats a disease or medical condition in an individual or, more generally, reduces symptoms, manages progression of the diseases or provides a nutritional, physiological, or medical benefit to the individual. The relative terms “improved,” “increased,” “enhanced” and the like refer to the effects of the composition disclosed herein relative to a composition lacking one or more ingredients and/or having a different amount of one or more ingredients, but otherwise identical.
- Compound of the Invention
- The present invention relates to a compound of structural formula (la)
- wherein R1=H or a halogen;
R2=an isoprenoid chain or a modified isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and - or a salt thereof for use in the prevention and/or treatment of a neurological disorder in an individual.
- In some embodiments, R1=H or a halogen; R2=an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=H or a halogen; R2=an isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=H or a halogen; R2=an isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=a halogen; R2=an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=a halogen; R2=an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen; and R3=H or OH.
- In some embodiments, R1=halogen; R2=an isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen; and R3=H or OH.
- In some embodiments, R1=halogen; R2=an isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen; and R3=H or OH.
- In some embodiments, R1=Cl; R2=an isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen; and R3=H.
- In one embodiment, compounds of structural formula (Ia) can be represented as follows:
- In one embodiment, the compound is for use in the prevention and/or treatment of a neurological disorder in an individual wherein lactate secretion is promoted.
- In one embodiment, the compound is for use in the prevention and/or treatment of a neurological disorder in an individual wherein lactate secretion from astrocytes is promoted.
- In one embodiment, the compound is for use in the prevention and/or treatment of a neurological disorder in an individual wherein lactate secretion is promoted from peripheral tissues.
- In one embodiment, the compound is for use in the prevention of cognitive decline in an individual wherein lactate secretion is promoted.
- In one embodiment, the individual is a human, in particular an elderly human individual or an infant human individual. In one embodiment, the individual is a companion animal.
- In one embodiment, the compound is a meroterpenoid. In one embodiment, the compound can be found in nature.
- In one embodiment, the compound is an isoprenoid phenol. In one embodiment, the compound is a prenyl phenol. In one embodiment, the compound is a terpenoid derivative.
- In one embodiment, the compound has structural formula (Ib).
- wherein R1=H or a halogen;
R2=a cyclized isoprenoid chain or a modified cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and - In some embodiments, R1=H or a halogen; R2=a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=H or a halogen; R2=a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=H or a halogen; R2=a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=a halogen; R2=a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen; and R3=H or OH.
- In some embodiments, R1=a halogen; R2=a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen; and R3=H or OH.
- In some embodiments, R1=a halogen; R2=a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen; and R3=H or OH.
- In some embodiments, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen; and R3=H.
- In some embodiments, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen; and R3=H.
- In some embodiments, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen; and R3=H.
- In one embodiment, compounds of structural formula (Ib) can be represented as follows:
- In one embodiment, R1=Cl.
- In one embodiment, R3=H.
- In one embodiment, R1=Cl and R3=H.
- In one embodiment, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and R3=H.
- In some embodiments, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and optionally oxygen; and R3=H.
- In some embodiments, R1=H or a halogen; R2=a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and optionally oxygen; and R3=H or OH.
- In some embodiments, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and oxygen; and R3=H.
- In some embodiments, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 10 carbon atoms, hydrogen, and oxygen; and R3=H.
- In some embodiments, R1=Cl; R2=a cyclized isoprenoid chain comprising 1 to 5 carbon atoms, hydrogen, and oxygen; and R3=H.
- For example, the compound may be selected from the list comprising CAS 26166-39-2 (Ascochlorin or Ilicicolin D); CAS 22562-68-1 (Antibiotic LL-Z 1272ε); CAS 165187-16-6 (Cylindrol B); CAS 22562-67-0 (Ilicicolin C); CAS 23887-67-4 (Ilicicolin E); CAS 22738-98-3 (Ilicicolin F); CAS 80557-12-6 (Grifolic acid); and CAS 22851-11-9.
- In a preferred embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D), or an analogue or derivative thereof.
- In a preferred embodiment, the compound is CAS 22562-67-0 (Illicicolin C), or an analogue or derivative thereof.
- In a preferred embodiment, the compound is CAS 22738-98-3 (Illicicolin F), or an analogue or derivative thereof.
- Ascochlorin and derivatives thereof can be found in or produced by fungal species, for example Acremonium sp., Acremoninum luculae, Ascochyta oiciae, Asochyta viciae, Cephalosporium diospyri, Cylindrocarpon lucidum, Fusarium sp., Nectria galligena, Nectria coccinea, Nigrosabulum globosum, Verticillium sp.
- In some embodiments, said compound has structural formula (Ic).
- wherein R1=H or a halogen;
R2=a cyclized isoprenoid chain with further hydroxylated side chain structure or a modified cyclized isoprenoid chain structure with further hydroxylated side chain structure and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optimally oxygen; and - In one embodiment, compounds of structural formula (Ic) can be represented as follows:
- In one embodiment, R1=Cl.
- In one embodiment, R3=H.
- In one embodiment, R2=a cyclized isoprenoid chain with further hydroxylated side chain structure and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optimally oxygen.
- In one embodiment, R1=Cl; R3=H; and R2=a cyclized isoprenoid chain with further hydroxylated side chain structure and further esterification comprising 1 to 19 carbon atoms, hydrogen, and oxygen.
- In one embodiment, R1=Cl; R3=H; and R2=a cyclized isoprenoid chain with further hydroxylated side chain structure and further esterification comprising 1 to 10 carbon atoms, hydrogen, and oxygen.
- In one embodiment, R1=Cl; R3=H; and R2=a cyclized isoprenoid chain with further hydroxylated side chain structure and further esterification comprising 1 to 5 carbon atoms, hydrogen, and oxygen.
- For example, said compound may be selected from the list comprising CAS 38561-36-3 (Deacetylchloronectrin); CAS 53730-27-1 (Hydroxyhydroascochlorin); CAS 38965-84-3 (Chloronectrin); CAS 1654004-69-9 (Nectchlorin A); CAS 165187-17-7 (Cylindrol A4); and CAS 1651819-33-8.
- In a preferred embodiment, the compound is CAS 38965-84-3 (Chloronectrin) or an analogue or derivative thereof.
- In some embodiments, said compound has structural formula (Id).
- wherein R1=H or a halogen;
R2=an open isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and - In one embodiment, compounds of structural formula (Id) can be represented as follows:
- For example, said compound may be selected from the list comprising CAS 83324-56-5 (Colletorin B); CAS 83324-48-5 (Colletochlorin B); CAS 22581-07-3 (Illicicolin B), CAS 22581-06-2 (Illicicolin A), CAS 1114927-87-5 (Chlorocylindrocarpol), and CAS1654004-70-2 (Nectchlorin B).
- The present invention also relates to a compound having a structural formula (II).
- wherein R1=phenethyl or a modified phenethyl side chain, and/or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen;
R2=H or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen;
R3=H or methyl; and
R4=an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen.
or a salt thereof for use in the prevention and/or treatment of a neurological disorder in an individual. - In one embodiment, compounds of structural formula (II) can be represented as follows:
- In one embodiment, the compound of structural formula (II) is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted.
- In one embodiment, the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion from astrocytes is promoted.
- In one embodiment, the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted in peripheral locations.
- In one embodiment, the compound is for use in the prevention of cognitive decline in an individual wherein lactate secretion is promoted.
- For example, said compound may be selected from the list comprising CAS 80489-90-3 (Amorfrutin); CAS 78916-41-3 (Amorfrutin A); CAS 78916-42-4 (Amorfrutin B=Amorfrutin B1); CAS 73436-04-1 (6-(2-phenylethyl)benzoic acid; 4-O-Demethylamorfrutin B); CAS 1189096-45-4 (Amorfrutin C); CAS 2077965-93-4 (Amorfrutin D); CAS 2074687-78-6 (4 Demethylamorfrutin D); and CAS 73436-07-4
- In a preferred embodiment, the compound is CAS 80489-90-3 (Amorfrutin) or CAS 73436-04-1 (6-(2-phenylethyl)benzoic acid=4-O-Demethylamorfrutin B).
- Amorfrutins may be obtained, for example, from the fruits of Amorpha fruticosa or the roots of Glycyrrhiza foetida.
- The present invention also relates to a compound having a structural formula (III).
- wherein R1=an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
- or a salt thereof for use in the prevention and/or treatment of a neurological disorder in an individual.
- In one embodiment, compounds of structural formula (III) can be represented as follows:
- In one embodiment, the compound of structural formula (III) is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted.
- In one embodiment, the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion from astrocytes is promoted.
- In one embodiment, the compound is for use in the prevention or treatment of a neurological disorder in an individual wherein lactate secretion is promoted in peripheral locations.
- In one embodiment, the compound is for use in the prevention of cognitive decline in an individual wherein lactate secretion is promoted.
- For example, said compound may be CAS 25999-31-9 (Lasalocid)
- There is also provided a composition comprising an effective amount of the compound of the invention, for use in the prevention or treatment of a neurological disorder in an individual.
- In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- In one embodiment, said composition is a pharmaceutical or nutraceutical composition.
- The terms “nutraceutical” combines the words “nutrition” and “pharmaceutical”. It is a food or food product that provides health and medical benefits, including the prevention and treatment of disease. A nutraceutical is a product isolated or purified from foods that is generally sold in medicinal forms not usually associated with food. A nutraceutical is demonstrated to have a physiological benefit or provide protection against chronic disease. Such products may range from isolated nutrients, dietary supplements and specific diets to genetically engineered foods, herbal products, and processed foods such as cereals, soups, and beverages.
- The term “nutraceutical” as used herein denotes usefulness in both nutritional and pharmaceutical fields of application. Thus, novel nutraceutical compositions can be used as supplements to food and beverages and as pharmaceutical formulations for enteral or parenteral application which may be solid formulations, such as capsules or tablets, or liquid formulations, such as solutions or suspensions.
- There is also provided a food or food extract enriched with a compound or composition of the invention. In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- Compound for Use in the Prevention or Treatment of Neurological and Other Disorders
- The compound of the invention can be used for the promotion of lactate secretion in an individual. In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- In particular, the compound of the invention can be used for the prevention or treatment of a neurological disorder, for memory dysfunction or for mild cognitive impairment in an individual.
- In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- In one embodiment, the compound of the invention is used for the prevention or treatment of a neurological disorder. Examples of a neurological disorder include disorders of the central nervous system such as addiction; arachnoid cysts; attention deficit/hyperactivity disorder (ADHD); Autism; Bipolar disorder; Catalepsy; Depression; Encephalitis; Epilepsy/Seizures; Infection; Locked-in syndrome; Meningitis; Migraine; Multiple sclerosis; Myelopathy. Neurological disorders may also include neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and Tourette's syndrome.
- The neurological disorder may be selected from addiction; arachnoid cysts; attention deficit/hyperactivity disorder (ADHD); Autism; Bipolar disorder; Catalepsy; Depression; Encephalitis; Epilepsy/Seizures; Infection; Locked-in syndrome; Meningitis; Migraine; Myelopathy. Neurological disorders may also include neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and Tourette's syndrome.
- The neurological disorder may be selected from attention deficit/hyperactivity disorder (ADHD); Autism; Bipolar disorder; Catalepsy; Infection; Locked-in syndrome; Meningitis; Migraine; Myelopathy.
- The neurological disorder may be selected from Alzheimer's disease, Huntington's disease, Parkinson's disease, and Tourette's syndrome.
- In some embodiments, the compound of the invention can also be used for the prevention or treatment of diabetes and/or diabetes-related disorders, particularly Type II diabetes, counteracting of insulin resistance, complications of diabetes, protection of pancreatic Langerhans islet beta-cells, antidiabetic therapies, therapy of syndrome X, diabetic neurosis, diabetic nephropathy, diabetic retinopathy, and for lifestyle-related diseases in an individual.
- In some embodiments, the compound of the invention is used for the protection of pancreatic Langerhans islet beta-cells, therapy of syndrome X, or diabetic neurosis.
- In one embodiment, the compound of the invention is used for the protection of pancreatic Langerhans islet beta-cells. In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- In some embodiments, the compound of the invention can also be used for the prevention or treatment of disorders relating to lipid metabolism, particularly to those of the ligand of retinoid X receptor, ligand of nuclear receptor, PPAR-Agonist, PPAR-Antagonist, ligands activating nuclear receptor super family, and to the improvement of lipid metabolism, and antilipemic disease in an individual.
- In some embodiments, the compound of the invention can also be used for the prevention or treatment of disorders related to vascular complications, particularly arteriosclerosis, hypertension, cerebrovascular diseases, hypotensive, hypertension, traumatic brain injury and cerebrovascular disorders in an individual.
- In some embodiments, the compound of the invention can also be used for the prevention or treatment of cancer, particularly to control tumors, and digestive cancers in an individual.
- In some embodiments, the compound of the invention can also be used for the prevention or treatment of inflammatory diseases, particularly rheumatoid arthritis, chronic inflammation, vascular chronic inflammation and the like in an individual.
- In some embodiments, the compound of the invention can also be used as a stimulator of AMPK activity in an individual.
- In some embodiments, the compound of the invention can also be used for the prevention or treatment of a series of other disorders, autoimmune diseases, anorectic, restenosis, myxedema, and cachexia in an individual.
- The present invention also relates to the use of a compound of structural formula (Ia), (Ib), (Ic), I(d), (II), or (III) in the preparation of a product for the promotion of lactate secretion in an individual. In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- The present invention also relates to the use of a compound of structural formula (Ia), (Ib), (Ic), I(d), (II), or (III) in the preparation of a product for the prevention or treatment of a neurological disorder in an individual. In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- The present invention also relates to the use of a compound of formula (Ia), (Ib), (Ic), I(d), (II), or (III) in the preparation of a diet product. In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- The present invention also relates to a method for the prevention or treatment of a neurological disorder comprising administering a compound of formula (Ia), (Ib), (Ic), I(d), (II), or (III) to an individual. In one embodiment, the compound is selected from Table 2. In one embodiment, the compound is CAS 26166-39-2 (Ascochlorin or Illicicolin D). In one embodiment, the compound is CAS 22562-67-0 (Illicicolin C). In one embodiment, the compound is CAS 22738-98-3 (Illicicolin F), In one embodiment, the compound is CAS 38965-84-3 (Chloronectrin).
- The invention can be illustrated by way of the following examples, which should not be seen as limiting the scope of the invention.
- Lactate Release—Screening Assay
-
FIG. 1 shows the lactate screening strategy and the general workflow of the lactate release from the astrocytes drug discovery screen. - Human astrocytoma cell line CCF-STTG1 was cultured at 37° C. in a humidified atmosphere (5% CO2) in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 50 μg/ml penicillin and 100 μg/ml streptomycin.
- CCF-STTG1 were seeded in 384-well plates. Two days later, the cells were washed 3 times and incubated 30 min in Krebs-Ringer bicarbonate HEPES (KRBH) buffer containing (in mM): 140 NaCl, 3.6 KCl, 0.5 NaH2PO4, 0.5 MgSO4, 1.5 CaCl2, 10 HEPES, 5 NaHCO3 (pH7.4) supplemented with 2.5 mM glucose. Then, the cells were maintained in the buffer in the presence of tested compounds. Supernatants were collected after 2 hours and were assessed for lactate concentration. Lactate concentration in the supernatants were determined by fluorescent enzymatic assay. Samples were diluted in assay reagent containing (in mM or U/ml)): 100 sodium phosphate (pH7.5), 0.1 EDTA, 0.05 Amplex UltraRed, 0.1 Lactate oxidase, 1.5 Horseradish Peroxidase.
- Fluorescence emission was measured at 600 nm after an excitation at 500 nm using Bioteck Synergie Neo multimode reader after 30 min at room temperature protected from direct light.
- Lactate Release—Counter Screen Assay
- The compounds were also tested in absence of cells using the same fluorescent enzymatic assay described previously to assess their auto fluorescence or their interaction with the enzymatic assay. Fluorescence emission was measured at 600 nm after an excitation at 500 nm using Bioteck Synergie Neo multimode reader after 30 min at room temperature and protected from direct light. Fluorescence was then compared to control fluorescence obtained in basal and stimulated cells.
- For the drug discovery counter screen, compounds diluted in KRBH were assessed for lactate release. The identified meroterpenoid compounds had no effect on the enzymatic assay in the absence of cells.
- Lactate Release—Orthogonal Assay
- CCF-STTG1 were seeded in 384-well plates. Two days later, the cells were washed 3 times and incubated 30 min in Krebs-Ringer bicarbonate HEPES (KRBH) buffer containing (in mM): 140 NaCl, 3.6KCl, 0.5 NaH2PO4, 0.5 MgSO4, 1.5 CaCl2, 10 HEPES, 5 NaHCO3 (pH7.4) supplemented with 2.5 mM glucose. The cells were maintained in the buffer in the presence of tested compounds. Supernatants were collected after 2 hours and assessed for lactate concentration. Lactate concentration in the supernatant was determined by a spectrophotometric enzymatic assay (lactate colorimetric assay kit II no. K627; BioVision, Milpitas, Calif. USA). In this kit, lactate is oxidized by lactate dehydrogenase to generate a product which interacts with a probe to produce a color (λmax=450 nm).
- Absorbance was measure after 30 min at 450 nm using Bioteck Synergie Neo multimode reader. Background absorbance obtained in the absence of kit was subtracted from each value.
- The stimulation of lactate secretion after treatment with meroterpenoid compounds was confirmed in an orthogonal assay based on another enzyme to measure lactate. The results of the lactate release measurement during the drug discovery screen for each compound and the results of lactate release measure with the orthogonal assay were correlated.
- Dose response curves were established for compounds identified in the screen to stimulate lactate secretion. The EC50 values for the stimulation of lactate secretion were determined using primary human IPS cell derived astrocytes.
- Differentiated human iPSCs (iCell astrocytes, and iCell cardiomyocytes) were obtained from Cellular Dynamics International (CDI, Madison, Wis., USA). iCell astrocytes were cultured in DMEM supplemented with 10% fetal calf serum and N2 complement. iCell cardiomyocytes were maintained in a medium supplied by CDI. Cell cultures were kept in a humidified atmosphere (5% CO2) at 37° C.
-
FIGS. 2A-2J shows lactate release. Dose response of compounds on lactate release from human iPSc derived into astrocyte fitted with a log (agonist) vs. response variable slope to extract efficacy (EC50). Mean±SEM in duplicate. - Toxicity—ATP Content
- iCell Cardiomyocytes were seeded in 384-well plates. Eight days later cells were treated for 24 hours with compounds. Cell viability was determined by the quantification of intracellular ATP after cell lysis. ATP was used as an indicator of metabolically active cells. ATP was measured using a luminescent cell viability assay (CellTiter-Glo®; BioRad, Hercules, Calif., USA). Luminescence was measured after 20 min in a Bioteck Synergie Neo multimode reader.
- Toxicity of the meroterpenoid compounds were evaluated in human IPS cell derived cardiomyocytes by measuring total ATP in cell lysates. Dose response experiments revealed that meroterpenoid compounds stimulated lactate secretion from astrocytes at concentrations several orders of magnitude below the concentration where they caused toxicity in cardiomyocytes.
-
FIGS. 3A-3I shows toxicity. Dose response of compounds on human iPSc derived into cardiomyocyte with evaluation of the ATP level using cell titer glow. Results were normalized between untreated cells (100%) and positive control (0%). - Hit Evaluation
- Table 1 and Table 2 show a list of compounds of interest
-
TABLE 1 Primary Orthogonal screen assay Reconfirmation Chemical name CAS Number % % % Ascochlorin 26166-39-2 not tested Ilicicolin F 22738-98-3 96 119 142 Ilicicolin C 22562-67-0 70 84 74 Chloronectrin 38965-84-3 104 68 97 22581-11-9 68 61 50 Antibiotic LL- 22562-68-1 72 68 83 Z1272ε Cylindrol B 165187-16-6 100 67 61 Lasalocid 25999-31-9 88 53 73 Amorfrutin 80489-90-3 85 80 122 4-O-Demethyl 73436-04-1 82 68 77 amorfrutin B -
TABLE 2 Astrocytes Cardiomyocytes Lactate release Toxicity CAS Number EC50 [M] logEC50 IC50 [M] log IC50 26166-39-2 1.1E−08 −7.9 1.2E−06 −5.9 22738-98-3 2.7E−08 −7.6 7.0E−06 −5.2 22562-67-0 1.5E−07 −6.8 7.1E−05 −4.2 38965-84-3 5.0E−07 −6.3 3.0E−05 −4.5 22581-11-9 1.4E−08 −7.9 3.2E−06 −5.5 22562-68-1 2.6E−06 −5.6 8.1E−05 −4.1 165187-16-6 6.7E−06 −5.2 3.1E−05 −4.5 25999-31-9 4.4E−06 −5.4 1.1E−05 −4.9 80489-90-3 3.2E−06 −5.5 4.7E−05 −4.3 73436-04-1 1.0E−05 −5.0 t.b.d t.b.d t.b.d: to be determined - The toxicity expressed in log IC50 (ATP content after 24 hours compound treatment on human iPSc derived into cardiomyocyte) was compared against the lactate release in log EC50 (lactate secretion after 2 hours compound treatment in human iPSc derived into astrocytes). Meroterpenoid tested compounds showed a range of concentration where they are active on lactate secretion by astrocytes and not toxic on cardiomyocytes.
-
FIG. 1 shows the lactate screening strategy -
FIGS. 2A-2J show lactate release. Y-axis: relative fluorescence unit, X-axis: logarithm concentration of the compound in molar. The structures of the compounds corresponding to graphs A-J are shown below. -
FIGS. 3A-3I show toxicity. Y-axis: relative fluorescence unit in percentage, X-axis: logarithm concentration of the compound in Molar. The structures of the compounds corresponding to graphs A-I are shown below.
Claims (13)
1. A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (Ia)
3. A method according to claim 1 , wherein the compound has a structural formula selected from the group consisting of:
a. Structural formula (Ib)
wherein R1=H or a halogen;
R2=a cyclized isoprenoid chain or a modified cyclized isoprenoid chain and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and
R3=H or OH;
b. Structural formula (Ic)
wherein R1=H or a halogen;
R2=a cyclized isoprenoid chain with further hydroxylated side chain structure or a modified cyclized isoprenoid chain structure with further hydroxylated side chain structure comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and
R3=H or OH; and
c. Structural formula (Id);
4. A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (II)
wherein R1=phenethyl or a modified phenethyl side chain, and/or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen;
R2=H or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen;
R3=H or methyl, and
R4=an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen
or a salt thereof.
5. A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (III)
6. A method according to claim 3 , wherein the compound has structural formula (Ib).
7. A method according to claim 6 , wherein R1=Cl, and R3=H.
8. A method according to claim 6 , wherein the compound is ascochlorin.
9. A method according to claim 6 , wherein the compound is CAS 22562-67-0 (Illicicolin C).
10. A method according to claim 6 , wherein the compound is CAS 22738-98-3 (Illicicolin F).
11. A method according to claim 1 , wherein lactate secretion is promoted.
12. A method according to claim 1 , wherein the lactate secretion from astrocytes is promoted.
13-22. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/971,033 US20230095374A1 (en) | 2017-09-15 | 2022-10-21 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17191464.1 | 2017-09-15 | ||
EP17191464 | 2017-09-15 | ||
PCT/EP2018/074805 WO2019053159A1 (en) | 2017-09-15 | 2018-09-13 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
US202016647229A | 2020-03-13 | 2020-03-13 | |
US17/971,033 US20230095374A1 (en) | 2017-09-15 | 2022-10-21 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/074805 Continuation WO2019053159A1 (en) | 2017-09-15 | 2018-09-13 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
US16/647,229 Continuation US11510890B2 (en) | 2017-09-15 | 2018-09-13 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230095374A1 true US20230095374A1 (en) | 2023-03-30 |
Family
ID=60042965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/647,229 Active 2038-12-31 US11510890B2 (en) | 2017-09-15 | 2018-09-13 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
US17/971,033 Pending US20230095374A1 (en) | 2017-09-15 | 2022-10-21 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/647,229 Active 2038-12-31 US11510890B2 (en) | 2017-09-15 | 2018-09-13 | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder |
Country Status (5)
Country | Link |
---|---|
US (2) | US11510890B2 (en) |
EP (1) | EP3681488A1 (en) |
JP (1) | JP7198805B2 (en) |
CN (1) | CN111050759A (en) |
WO (1) | WO2019053159A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111302942B (en) * | 2020-04-09 | 2022-03-01 | 中国热带农业科学院热带生物技术研究所 | Compound with PTP1B inhibitory activity and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55113712A (en) * | 1979-02-23 | 1980-09-02 | Chugai Pharmaceut Co Ltd | Remedy for copper metabolism disorder |
JPH0816057B2 (en) * | 1992-09-10 | 1996-02-21 | 田村 學造 | Glycation inhibitors |
JPH09165332A (en) * | 1995-12-15 | 1997-06-24 | Tomoyoshi Hosokawa | Antiprotozoal agent comprising isoprenoid-based antibiotic as active ingredient |
CA2355299A1 (en) * | 1998-12-14 | 2000-06-22 | Takafumi Uchida | Novel ligands of nuclear receptor |
WO2000053563A1 (en) * | 1999-03-11 | 2000-09-14 | Nuclear Receptor Research Limited | Novel ligands of nuclear receptors ppar's |
JP2006213644A (en) * | 2005-02-03 | 2006-08-17 | Nrl Pharma Inc | Ap-1 activity inhibitor |
EP1762558A1 (en) * | 2005-09-07 | 2007-03-14 | NRL Pharma, Inc. | Process for preparing transcription factors and their use |
CN101422450B (en) * | 2008-10-09 | 2011-11-09 | 广州市允中投资发展有限公司 | Cajanus cajan L. natural medicine with blood sugar reduction and weight reduction function |
US9662314B2 (en) * | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
CN102786414B (en) * | 2012-08-15 | 2014-07-16 | 四川大学 | Compound for treating and/or preventing neurodegenerative related disease |
-
2018
- 2018-09-13 JP JP2020508497A patent/JP7198805B2/en active Active
- 2018-09-13 US US16/647,229 patent/US11510890B2/en active Active
- 2018-09-13 EP EP18766267.1A patent/EP3681488A1/en active Pending
- 2018-09-13 WO PCT/EP2018/074805 patent/WO2019053159A1/en unknown
- 2018-09-13 CN CN201880057034.0A patent/CN111050759A/en active Pending
-
2022
- 2022-10-21 US US17/971,033 patent/US20230095374A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020533279A (en) | 2020-11-19 |
US20200405676A1 (en) | 2020-12-31 |
WO2019053159A1 (en) | 2019-03-21 |
US11510890B2 (en) | 2022-11-29 |
CN111050759A (en) | 2020-04-21 |
JP7198805B2 (en) | 2023-01-04 |
EP3681488A1 (en) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maczurek et al. | Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease | |
Tsai et al. | Antioxidative and anti-inflammatory protection from carnosine in the striatum of MPTP-treated mice | |
US6335361B1 (en) | Method of treating benign forgetfulness | |
Yi et al. | L-arginine and Alzheimer's disease | |
US20120148685A1 (en) | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders | |
US20200129463A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
US20230095374A1 (en) | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder | |
Głombik et al. | Mitochondria-targeting therapeutic strategies in the treatment of depression | |
Ariyanfar et al. | Review on headache related to dietary supplements | |
Latham et al. | Neuroprotective effects of carnitine and its potential application to ameliorate neurotoxicity | |
Kones | Mitochondrial therapy for Parkinson’s disease: Neuroprotective pharmaconutrition may be disease-modifying | |
Zheng et al. | B vitamins supplementation can improve cognitive functions and may relate to the enhancement of transketolase activity in a rat model of cognitive impairment associated with high-fat diets | |
AU2017336291A1 (en) | Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia | |
Mesripour et al. | Monosodium glutamate influences depressive behavior of two age groups of mice in forced swimming test: Vitamin B6 could remedy the situation | |
Patel et al. | Can?-Lipoic Acid Mitigate Progression of Aging-Related Decline Caused by Oxidative Stress | |
US20230002303A1 (en) | Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder | |
EP3388061A1 (en) | Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia | |
Murray | Pyrroloquinoline quinone (PQQ): The next essential nutrient and supplement superstar | |
US20220362188A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
US20220256888A1 (en) | Compositions and methods using at least one of oleuropein or a metabolite thereof to treat or prevent muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise | |
de Oliveira | Mitochondrial Dysfunction and Nanotherapeutics: Aging, Diseases, and Nanotechnology-Related Strategies in Mitochondrial Medicine | |
Carrieri | The role of nutritional factors in cognitive aging of older adults | |
Gambini et al. | Resveratrol in Experimental Models and Humans | |
WO2023213780A1 (en) | Compositions and methods using at least one of oleuropein or a metabolite thereof to treat or prevent muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise | |
Newmire | The acute effects of l-Leucine and l-Isoleucine on glycemic responses in healthy and inactive adults |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: GLIAPHARM SA, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOCIETE DES PRODUITS NESTLE SA;REEL/FRAME:062208/0283 Effective date: 20221218 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |